Detalles de la búsqueda
1.
Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.
Eur J Haematol
; 107(1): 92-103, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728732
2.
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Leuk Lymphoma
; 61(3): 714-720, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31686559
3.
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.
PLoS One
; 13(12): e0208507, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30517181
4.
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.
Clinicoecon Outcomes Res
; 9: 163-172, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28280374
5.
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.
Curr Med Res Opin
; 32(1): 147-54, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26455472
6.
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
J Med Econ
; 18(10): 787-96, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25934147
Resultados
1 -
6
de 6
1
Próxima >
>>